D. Stewart

Molecular Biology · 2007–2014

A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom D. Stewart trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Z. Siddik
  2. Paul Polakis

Papers from D. Stewart's perspective

Ordered by how strongly the researchers D. Stewart trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. (Journal of Clinical Oncology)
  2. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. (Journal of Clinical Oncology)
  3. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. (Journal of Clinical Oncology)
  4. Is cisplatin-induced cell death always produced by apoptosis? (Molecular Pharmacology)
  5. Cisplatin: mode of cytotoxic action and molecular basis of resistance (Oncogene)
  6. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals (Proceedings of the National Academy of Sciences of the United States of America)
  7. Cancer burden in the year 2000. The global picture. (European Journal of Cancer)
  8. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  9. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
  10. [New guidelines to evaluate the response to treatment in solid tumors]. (Bulletin du Cancer)

Their papers